132,234 Shares in Esperion Therapeutics, Inc. (NASDAQ:ESPR) Bought by Virtu Financial LLC

Virtu Financial LLC acquired a new stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 132,234 shares of the biopharmaceutical company’s stock, valued at approximately $291,000. Virtu Financial LLC owned approximately 0.07% of Esperion Therapeutics at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the stock. Public Employees Retirement System of Ohio purchased a new stake in shares of Esperion Therapeutics in the third quarter valued at about $606,000. Anson Funds Management LP purchased a new stake in Esperion Therapeutics in the 3rd quarter valued at about $540,000. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Esperion Therapeutics by 71.0% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 711,278 shares of the biopharmaceutical company’s stock worth $1,174,000 after buying an additional 295,378 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Esperion Therapeutics by 66.8% in the 3rd quarter. Wellington Management Group LLP now owns 602,936 shares of the biopharmaceutical company’s stock worth $995,000 after buying an additional 241,512 shares during the last quarter. Finally, Wasatch Advisors LP grew its holdings in shares of Esperion Therapeutics by 38.4% in the third quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock valued at $38,521,000 after acquiring an additional 6,483,070 shares in the last quarter. 47.39% of the stock is currently owned by institutional investors.

Esperion Therapeutics Trading Down 1.2 %

Esperion Therapeutics stock opened at $1.61 on Friday. The firm’s 50 day simple moving average is $1.79 and its 200 day simple moving average is $2.07. Esperion Therapeutics, Inc. has a 1-year low of $1.47 and a 1-year high of $3.94. The firm has a market capitalization of $318.54 million, a PE ratio of -2.52 and a beta of 1.04.

Analyst Ratings Changes

ESPR has been the topic of several research analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $6.00 price objective on shares of Esperion Therapeutics in a research report on Friday, December 13th. Cantor Fitzgerald assumed coverage on shares of Esperion Therapeutics in a report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 price objective for the company. JMP Securities reissued a “market outperform” rating and set a $4.00 target price (down from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a research note on Thursday, March 20th. Finally, The Goldman Sachs Group started coverage on Esperion Therapeutics in a research note on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 target price on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $6.75.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.